Prognostic Factors in Soft Tissue Sarcoma

Teixeira, Luiz Eduardo Moreira; Vilela, J. C.; Araújo, Ivana Duval

doi:10.5772/25742

Soft Tissue Tumors 2011

DOI: 10.5772/25742

|View full text |Cite

Prognostic Factors in Soft Tissue Sarcoma

Luiz Eduardo Moreira Teixeira¹,

J. C. Vilela²,

Ivana Duval Araújo³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Pazopanib in the treatment of soft tissue sarcoma

Schöffski¹

2012

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Patients with advanced metastatic soft tissue sarcoma (STS) have a poor prognosis, and in the last two decades of the 20th century their overall survival has remained unchanged. Improved treatments are needed for these patients and for preventing metastases in earlier stages of disease. Numerous novel agents and new combination regimens are undergoing clinical testing in STS. Some of these agents show promising activity. Pazopanib is one such agent that has undergone Phase II and III evaluations in advanced STS. Pazopanib is a multi-tyrosine kinase inhibitor, blocking various signaling pathways, thereby preventing angiogenesis and metastasis, and inhibiting tumor cell growth and survival. In a Phase II study, pazopanib demonstrated activity in patients with advanced leiomyosarcomas, synovial sarcomas and other eligible STSs. This activity was confirmed in a Phase III trial, where pazopanib significantly extended the median progression-free survival versus placebo in a variety of STS subtypes.

show abstract

Pazopanib in the treatment of soft tissue sarcoma

Schöffski¹

2012

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prognostic Factors in Soft Tissue Sarcoma

Cited by 1 publication

References 10 publications

Pazopanib in the treatment of soft tissue sarcoma

Pazopanib in the treatment of soft tissue sarcoma

Contact Info

Product

Resources

About